Name: Moderna shares jump after U.S. ups funding for coronavirus vaccine by $472 million
Brand: cnbc.com
SKU: cnbc-com-606
Availability: OnlineOnly

critic

Moderna shares jump after U.S. ups funding for coronavirus vaccine by $472 million

preview

Key PointsModerna CEO Stephane Bancel on kick off of phase three Covid-19 vaccine trial&nbsp;shares rose nearly 6% on Monday after the biotech company announced it received an additional $472 million from the The additional funding from the Biomedical Advanced Research and Development Authority will support Moderna's late-stage development of its vaccine including the phase three study, which begins Monday and will include at least 30,000 participants. Moderna from the federal agency in April.&nbsp;a day agoThere are no FDA-approved drugs or vaccines for the coronavirus, which has infected more than 16 million people worldwide and killed at least&nbsp;648,900 in less than seven months, according to data compiled by Johns Hopkins University. There are more than 150 vaccines under development, according to the World Health Organization, with 25 vaccines already in human trials.Shares of Moderna were up 5.8% to $77.43 in midmorning trading.Moderna's&nbsp;experimental vaccine, which is being developed with the help of the&nbsp;National Institutes of Health, contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus.It became&nbsp;the first candidate to enter a phase one human trial in March. Pharmaceutical giant Pfizer and AstraZeneca, which are also conducting human trials for potential coronavirus vaccines, have previously received funding from BARDA.The results from Moderna's late-stage trial could be released as soon as October, Moderna CEO&nbsp;Stephane Bancel said Monday during an interview on CNBC's "" "It's a really optimistic scenario. It could be November. Again, at this stage, it's impossible for us to know precisely. It will depend on the event rate, the attack rate of infection."The phase three trial will enroll&nbsp;30,000 participants across 87 locations, according to ClinicalTrials.gov. Participants will receive a 100 microgram dose of the potential vaccine on the first day and another 29 days later. Some patients in the trial will also receive a placebo.Earlier this month,&nbsp;the biotech company released promising data on the vaccine trial, saying it generated a "robust" immune response.&nbsp;The vaccine candidate produced neutralizing antibodies, which scientists believe is important for building immunity against the virus, in all 45 patients tested in the trial, Moderna scientists reported in the New England Journal of Medicine.The company said it remains on track to deliver between 500 million and 1 billion doses per year starting next year.

Key PointsModerna CEO Stephane Bancel on kick off of phase three Covid-19 vaccine trial&nbsp;shares rose nearly 6% on Monday after the biotech company announced it received an additional $472 million from the The additional funding from the Biomedical Advanced Research and Development Authority will support Moderna's late-stage development of its vaccine including the phase three study, which begins Monday and will include at least 30,000 participants. Moderna from the federal agency in April.&nbsp;a day agoThere are no FDA-approved drugs or vaccines for the coronavirus, which has infected...

public

Will Feuer

Berkeley Lovelace Jr.

cnbc.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Moderna shares jump after U.S. ups funding for coronavirus vaccine by $472 million

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS